The Brief
What Tempus AI Multiomics does and why it matters
Tempus multiomics platform integrates genomic, transcriptomic, and proteomic data with AI to create comprehensive tumor profiles. Oncologists receive the most complete picture of each cancer for optimal treatment selection.
Builder’s Brief
Tempus AI Multiomics is a healthcare tool on Falcoscan. AI multi-omics platform for comprehensive cancer profiling. Falcoscan rates Tempus AI Multiomics with an Opportunity score of 86/100, a Saturation score of 6/100, and a Wrapper-risk score of 11/100. Market signal: hot. Tempus AI Multiomics is founded in 2024, currently at Series_a stage. Pricing: Paid. Rating 4.7/5 across 3 tracked views.